Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections

Nature Medicine

Volumn 21, Issue 9, 2015, Pages 1071-1075

  Dalli, Jesmond ^a   Chiang, Nan ^a   Serhan, Charles N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALKADIENE; ATORVASTATIN; CARBON 13; CELL PROTEIN; CYCLOOXYGENASE 2; DOCOSAPENTAENOIC ACID; INFLAMMASOME; RESOLVIN; UNCLASSIFIED DRUG; DOCOSAHEXAENOIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL BOND; COCULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; ESCHERICHIA COLI INFECTION; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; INNATE IMMUNITY; MOUSE; NEUTROPHIL; NITROSYLATION; NONHUMAN; PHAGOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; SURVIVAL RATE; ANIMAL; CHEMISTRY; IMMUNOLOGY; MALE; MORTALITY; PHYSIOLOGY;

ANIMALS; ATORVASTATIN CALCIUM; DOCOSAHEXAENOIC ACIDS; ENDOTHELIAL CELLS; ESCHERICHIA COLI INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNITY, INNATE; MALE; MICE; NEUTROPHILS;

EID: 84941022675     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3911     Document Type: Article

References (32)

1. Ward, P.A. New approaches to the study of sepsis. EMBO Mol. Med. 4, 1234-1243 (2012).
2. Magill, S.S. et al. Multistate point-prevalence survey of health care-associated infections. N. Engl. J. Med. 370, 1198-1208 (2014).
3. Fullerton, J.N., O'Brien, A.J. & Gilroy, D.W. Lipid mediators in immune dysfunction after severe inflammation. Trends Immunol. 35, 12-21 (2014).
4. Serhan, C.N. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92-101 (2014).
5. Tabas, I. & Glass, C.K. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339, 166-172 (2013).
6. Lemaitre, R.N. et al. Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. PLoS Genet. 7, e1002193 (2011).
7. Dalli, J., Colas, R.A. & Serhan, C.N. Novel n-3 immunoresolvents: structures and actions. Sci Rep. 3, 1940 (2013).
8. Chiang, N. et al. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484, 524-528 (2012).
9. Serhan, C.N. et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025-1037 (2002).
10. Sadik, C.D., Kim, N.D. & Luster, A.D. Neutrophils cascading their way to inflammation. Trends Immunol. 32, 452-460 (2011).
11. Borregaard, N. Neutrophils, from marrow to microbes. Immunity 33, 657-670 (2010).
12. Mead, P.S. et al. Food-related illness and death in the United States. Emerg. Infect. Dis. 5, 607-625 (1999).
13. Markworth, J.F. et al. Human inflammatory and resolving lipid mediator responses to resistance exercise and ibuprofen treatment. Am. J. Physiol. Regul. Integr. Comp. Physiol. 305, R1281-R1296 (2013).
14. Clària, J. & Serhan, C.N. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad. Sci. USA 92, 9475-9479 (1995).
15. Kandasamy, K. et al. Atorvastatin prevents vascular hyporeactivity to norepinephrine in sepsis: role of nitric oxide and a1-adrenoceptor mRNA expression. Shock 36, 76-82 (2011).
16. Atar, S. et al. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am. J. Physiol. Heart Circ. Physiol. 290, H1960-H1968 (2006).
17. Lins, R.L. et al. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrol. Dial. Transplant. 18, 967-976 (2003).
18. Ji, Y., Akerboom, T.P., Sies, H. & Thomas, J.A. S-nitrosylation and S-glutathiolation of protein sulfhydryls by S-nitroso glutathione. Arch. Biochem. Biophys. 362, 67-78 (1999).
19. von Moltke, J. et al. Rapid induction of inflammatory lipid mediators by the inflammasome in vivo. Nature 490, 107-111 (2012).
20. Henriksbo, B.D. et al. Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance. Diabetes 63, 3742-3747 (2014).
21. Cederberg, H. et al. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6-year follow-up study of the METSIM cohort. Diabetologia 58, 1109-1117 (2015).
22. Gryglewski, R.J. & Mackiewicz, Z. Vane's blood-bathed organ technique adapted to examine the endothelial effects of cardiovascular drugs in vivo. Pharmacol. Rep. 62, 462-467 (2010).
23. Ye, Y. et al. Activation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2. Prostaglandins Other Lipid Mediat. 84, 43-53 (2007).
24. Morikawa, S. et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J. Atheroscler. Thromb. 9, 178-183 (2002).
25. Chiang, N. et al. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484, 524-528 (2012).
26. Serhan, C.N. et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025-1037 (2002).
27. Colas, R.A., Shinohara, M., Dalli, J., Chiang, N. & Serhan, C.N. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am. J. Physiol. Cell Physiol. 307, C39-C54 (2014).
28. Oh, S.F., Pillai, P.S., Recchiuti, A., Yang, R. & Serhan, C.N. Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J. Clin. Invest. 121, 569-581 (2011).
29. Corey, E.J., Bakshi, R.K. & Shibata, S. Highly enantioselective borane reduction of ketones catalyzed by chiral oxazaborolidines. Mechanism and synthetic implications. J. Am. Chem. Soc. 109, 5551-5553 (1987).
30. Gangemi, S. et al. Physical exercise increases urinary excretion of lipoxin A4 and related compounds. J. Appl. Physiol. 94, 2237-2240 (2003).
31. Hemler, M.E. & Lands, W.E. Protection of cyclooxygenase activity during heme-induced destabilization. Arch. Biochem. Biophys. 201, 586-593 (1980).
32. Ji, Y., Akerboom, T.P., Sies, H. & Thomas, J.A. S-nitrosylation and S-glutathiolation of protein sulfhydryls by S-nitroso glutathione. Arch. Biochem. Biophys. 362, 67-78 (1999).